Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

On Aug 13, we upgraded medical devices company, Covidien (COV - Analyst Report) to Neutral from Underperform based on its improved third-quarter results.

Why the Upgrade?

Covidien posted adjusted earnings per share from continuing operations of 91 cents for the third quarter of fiscal 2013 (flat year over year), which beat the Zacks Consensus Estimate by a penny. Revenues increased 3% (up 5% in constant currency) to $2,578 million but were slightly below the Zacks Consensus Estimate of $2,587 million.

Over the past four quarters, this Zacks Rank #3 (Hold) stock has delivered an average surprise of 2.18%. The Zacks Consensus Estimate for fiscal 2013 earnings has gone up 0.5% to $3.71 per share in the last 30 days. However, the same has declined by 0.7% for fiscal 2014.

We believe that improvement in the core Medical Device segment, despite a soft underlying market, has driven investor confidence. Revenues from the larger Medical Devices segment grew 4% (up 6% in constant currency) to $2,139 million in the third quarter of fiscal 2013. The division is benefiting from new products and higher volumes.

Further, the successful spin-off of its Pharma unit should help the company to focus on its high-margin surgical products portfolio and execute growth plans. Additionally, gains from acquisitions and expansion into emerging markets should propel growth.

However, the company remains exposed to pricing/volume and foreign exchange headwinds and faces stiff competition. Moreover, the medical device tax and higher investment-related expenses are likely to pressurize margins going forward.

Other Stocks to Consider

Other medical stocks such as Hanger (HGR - Analyst Report) and Alere (ALR - Snapshot Report), with a Zacks Rank #1 (Strong Buy) along with Hospira (HSP - Analyst Report), carrying a Zacks Rank #2 (Buy), are worth considering.
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%